

DRAFT AGENDA: Understanding the Biology, Antifungal Resistance and Clinical Implications of *Candida auris*

January 28-29, 2020
5601 Fishers Lane, Rockville, MD

1D13

Day 1

Time	Session/Topic	Speaker/Moderator
Welcome, introductions, workshop objectives		
7:00-8:00am	Registration	
8:00-8:10am	Opening Remarks	Dennis Dixon, PhD <i>NIAID/NIH</i>
	Workshop Objectives and NIAID Mycology Portfolio	Dona Love, PhD <i>NIAID/NIH</i>
Session 1: Emergence and unique features of the first MDR fungal pathogen		
8:10-9:40am	Candida auris: international perspective 20 min talk	Nelesh Govender, MD <i>National Institute for Communicable Diseases, South Africa</i>
	C. auris: Challenges and lessons learned from other MDROs 20 min talk	David Perlin, PhD <i>Center for Discovery and Innovation</i>
	US experience with C. auris 20 min talk	Mary Hayden, MD <i>Rush University</i>
	Candida auris: unique genomics of an emerging MDR pathogen 20 min talk	Christina Cuomo, PhD <i>Broad Institute</i>
9:40-10:00am	Moderated panel discussion of Session 1	Julie Segre
10:00-10:20am	Coffee break	
Session 2: Epidemiological and Clinical Characteristics		
10:20-11:50am	Epidemiology Overview 20 min talk	Tom Chiller/Brendan Jackson <i>CDC</i>
	UK outbreak experience 20 min talk	Silke Schelenz <i>Imperial College School of Public Health, UK</i>
	US Clinical Experience 20 min talk	Dana Mazo <i>Mt Sinai, NYC</i>
	Genomic epidemiology 20 min talk	Julie Segre, PhD <i>NIAID</i>
11:50-12:10pm	Moderated panel discussion of Session 2	Moderator:

12:10-1:00pm	Lunch	
Session 3: Diagnostics and decolonization		
1:00-2:55pm	Introduction to laboratory challenges 10 min talk	Beth Berkow, PhD CDC
	Strategies to mitigate transmission and decolonization of MDRO pathogens 20 min talk	Susan S Huang, MD <i>UC Irvine</i>
	Screening and detection in NY outbreak 20 min talk	Eleanor Adams, MD, MPH <i>NY State Department of Health</i>
	Novel diagnostic platforms (geneXpert) 20 min talk	David Alland, MD, MSc <i>Rutgers</i>
	Cross kingdom vaccine as a decolonization strategy 20 min talk	Jack Edwards, MD <i>UCLA</i>
	FDA Regulatory considerations fungal Dx 15 min talk	TBD
2:55-3:15pm	<i>Moderated panel discussion of Session 3</i>	Moderator: Beth Berkow
3:15-3:45	Coffee Break	
Session 4: Resistance, immune recognition and novel therapeutics		
3:45-5:10 pm	Candida auris: drug development considerations 20 min talk	David Andes, MD <i>University of Wisconsin</i>
	Skin animal model, immunology 20 min talk	Mihalis Lionaikis, MD., Sc.D. <i>NIAID</i>
	Biofilm and neutrophil recognition 20 min talk	Jeniel Nett, MD, PhD <i>University of Wisconsin</i>
	Tolerance and drug resistance 20 min talk	P. David Rogers, PharmD., PhD <i>University of Tennessee</i>
5:10-5:30pm	<i>Moderated panel discussion of Session 4</i>	Moderator
End of Day 1 Optional Networking Dinner in evening		

DRAFT AGENDA:**Understanding the Biology, Antifungal Resistance and Clinical Implications of *Candida auris***

January 28-29, 2020
5601 Fishers Lane, Rockville, MD

1D13**Day 2****Session 5: Therapeutics in the pipeline**

Time	Session/Topic	Speaker/Moderator
8:00-9:10am	Fungal clinical trials overview clinical trials 15 min talk	Peter Pappas, MD <i>University of Alabama</i>
	Regulatory path for therapeutics 15 min talk	David Angulo, MD <i>Scynexis, Inc</i>
	Amplyx—strategies for therapeutics 15 min talk	<i>Karen Shaw</i>
	FDA Regulatory considerations fungal Tx 15 min talk	Edward Weinstein, MD FDA, CDER
9:10-9:30am	<i>Moderated discussion</i>	
9:30-10:00am	Coffee Break	
Session 6: Break out session & meeting wrap up		
10:00-11:15am	Group breakout sessions to discuss key gaps/priorities	
11:15-12:30pm	Return to main room for group presentations	
12:30pm	Meeting adjourn	

End of Meeting